SI-BONE Announces Launch of Public Offering of Common Stock
January 21 2020 - 3:01PM
SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based
medical device company dedicated to solving musculoskeletal
disorders of the sacropelvic anatomy, today announced that it has
commenced an underwritten public offering of 4,300,000 shares of
its common stock. In addition, SI-BONE expects to grant the
underwriters a 30-day option to purchase up to an additional
645,000 shares of common stock on the same terms and conditions. Of
the shares of common stock being offered, 1,809,947 shares are
being offered by selling stockholders and 2,490,053 shares are
being offered by SI-BONE. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed or as to the actual size or terms of the
offering.
Morgan Stanley and BofA Securities are acting as
joint book-running managers.
A shelf registration statement relating to the
shares being sold in this offering was filed with the U.S.
Securities and Exchange Commission on December 26, 2019, and was
declared effective on January 2, 2020. The offering will be made
only by means of a prospectus supplement and accompanying
prospectus. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with
the SEC and will be available for free on the SEC’s
website located at http://www.sec.gov. When available,
electronic copies of the preliminary prospectus supplement and
accompanying prospectus relating to the proposed public offering
may be obtained from Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New
York 10014; or from BofA Securities, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte NC 28255-0001, Attn:
Prospectus Department, or email at
dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SI-BONE
SI-BONE is a medical device company that
pioneered minimally invasive surgery of the SI joint with the iFuse
Implant System.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements relating to SI-BONE’s expectations
regarding the proposed public offering. These statements are
subject to significant risks and uncertainties and actual results
could differ materially from those projected. SI-BONE cautions
investors not to place undue reliance on the forward-looking
statements contained in this release. These risks and uncertainties
include, without limitation, risks and uncertainties related to
market conditions, the risk that the proposed public offering will
not be consummated on the terms or in the amounts contemplated or
otherwise, and the satisfaction of customary closing conditions
related to the proposed public offering. Risks and uncertainties
relating to SI-BONE and its business can be found in the “Risk
Factors” section of SI-BONE’s Form 10-Q for the quarter ended
September 30, 2019, filed with the SEC on November 12, 2019, and in
the preliminary prospectus contained in the registration statement
related to the proposed public offering filed with the SEC on
January 21, 2020. SI-BONE undertakes no duty or obligation to
update any forward-looking statements contained in this release as
a result of new information, future events or changes in SI-BONE’s
expectations, except as required by law.
Investor Contact:Lynn Lewis or
Carrie Mendivilinvestors@SI-BONE.com
Media Contact:Joe
Powersjpowers@si-bone.com
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jul 2023 to Jul 2024